Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil for prevention and treatment of rejection in high-risk corneal allograft
ChiCTR1900026319Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate mofetil in keratoplasty rejection (CGR) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Rejection rate and time to occurrence within 1 year. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
keratoplasty rejection (CGR)
Beyond the preview
Go deeper on ChiCTR1900026319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026319.